Status:
COMPLETED
Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Conditions:
Essential Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Resistant hypertension is defined as hypertension not controlled (i.e. blood pressure not below 140/90 mmHg) with the use of adequate doses of at least three different anti-hypertensives including a d...
Detailed Description
see above
Eligibility Criteria
Inclusion
- Casual blood pressure \>=140/90 despite effective triple therapy including an ACEI/ARB and a diuretic
Exclusion
- Contraindication for eplerenone
- Creatinine-Clearance \< 60 ml/min
- Diabetes mellitus
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00138944
Start Date
January 1 2007
End Date
July 1 2008
Last Update
April 17 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CRC Medical Department IV
Erlangen, Germany, 91054